|
Medtronic
Announces ACC 2009 Presentations
Cardiovascular Innovations to
Feature Prominently at U.S. Cardiology Meeting
Highlights Include Presentations on Endeavor Stent and Export Aspiration
Catheter
|
 |
Endeavor
drug-eluting stent
|
|
March 27, 2009 --
Medtronic, Inc. (NYSE: MDT), today announced highlights of clinical
data
presentations scheduled for the 2009 American College of Cardiology
(ACC) meeting that feature the company’s cardiovascular innovations,
including the Endeavor Drug-Eluting Stent (DES) and the Export
Aspiration Catheter. ACC.09 takes place in Orlando March 28–31
at the Orange County Convention Center.
|
Late-Breaking Clinical Trials
Clinical data on the Endeavor DES will be presented in the following late-breaking clinical trial session:
Sunday, March 29
i.2 Plenary.2406 – Valencia Ballroom W415
- ZEST /
08:00 – 08:12
(2406-7)
Comparison of Sirolimus- and Paclitaxel-Eluting Stents Versus
Zotarolimus-Eluting Stents in Real World Practice: The ZEST Randomized
Controlled Trial, by Seung-Jung Park (Seoul, South Korea)
et al.
Oral and Poster Contributions
Additional data related to Medtronic’s cardiovascular medical technologies
will also be released in the following i.2 poster contributions starting
Saturday:
- E-Five Registry
(2510-644) Two-Year Extended Follow-Up in Patients Receiving a Zotarolimus-Eluting
Stent in the E-Five Registry, by Martin Rothman (London, England)
et al.
(2501-521) Predictors of Major Adverse
Cardiac Events in a Real-World Population Receiving the
Zotarolimus-Eluting Stent: Data from the E-Five
Registry, by Chaim Lotan (Jerusalem, Israel) et al.
(2501-533)
The Safety and Efficacy of the Zotarolimus-Eluting Stent
in Elderly Patients: 12-Month Outcomes from the E-Five Registry,
by
Chaim
Lotan (Jerusalem, Israel) et al.
(2520-787) The Effect of Renal Impairment
on Outcomes from the Real-World E-Five Registry, by Martin
Rothman (London, England) et al.
- SENS
Registry
(2501-543) Outcome of Non-cardiac Surgical Procedure
and Brief Interruption of Dual Antiplatelet Agents within 12
Months Following Endeavor
Stent Implantation (SENS): A Multicenter Study, by
Jin Won Kim (Seoul,
South Korea) et al.
- TAPAS-II
(2514-721) One-Year Follow-Up
of Thrombus Aspiration During Primary Percutaneous Coronary Intervention
in Acute Non-ST-Elevation Myocardial
Infarction Study, by Pieter Vlaar (Groningen, the Netherlands)
et al.
These posters will be on display at various times on Sunday and Monday.
In addition, Medtronic will feature highlights of its current and future cardiovascular
innovations at ACC.09 (booth number 2743).
About Medtronic
Medtronic, Inc. (www.medtronic.com)
headquartered in Minneapolis, is the global leader in medical technology – alleviating
pain, restoring health and extending life for millions of people around the
world.
Any
forward-looking statements are subject to risks and uncertainties such as those
described in Medtronic’s Annual Report on Form 10-K for the year ended
April 25, 2008. Actual results may differ materially from anticipated results.
Source: Medtronic,
Inc.
|
